160 related articles for article (PubMed ID: 35623105)
1. Effectiveness and safety of edoxaban therapy in daily-care patients with atrial fibrillation. Results from the DRESDEN NOAC REGISTRY.
Köhler C; Tittl L; Marten S; Naue C; Spindler M; Stannek L; Fache K; Beyer-Westendorf J
Thromb Res; 2022 Jul; 215():37-40. PubMed ID: 35623105
[TBL] [Abstract][Full Text] [Related]
2. Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Reimitz PE; Kirchhof P;
J Cardiovasc Med (Hagerstown); 2019 Feb; 20(2):97-104. PubMed ID: 30540648
[TBL] [Abstract][Full Text] [Related]
3. Rates, management and outcome of bleeding complications during edoxaban therapy in daily care - results from the DRESDEN NOAC REGISTRY.
Beyer-Westendorf J; Marten S; Naue C; Tittl L; Hänsel U; Beyer-Westendorf I; Mizera H; Schreier T; Festerling E; Reitter A; Spindler M; Bornhäuser M
Thromb Res; 2020 Jun; 190():91-98. PubMed ID: 32335423
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).
De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Kerschnitzki M; Reimitz PE; Kirchhof P;
BMC Cardiovasc Disord; 2019 Jul; 19(1):165. PubMed ID: 31299906
[TBL] [Abstract][Full Text] [Related]
5. Patterns of atrial fibrillation anticoagulation with rivaroxaban - 7-year follow-up from the Dresden NOAC registry.
Tittl L; Marten S; Naue C; Beyer-Westendorf J
Thromb Res; 2024 Apr; 236():61-67. PubMed ID: 38394987
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry.
Hecker J; Marten S; Keller L; Helmert S; Michalski F; Werth S; Sahin K; Tittl L; Beyer-Westendorf J
Thromb Haemost; 2016 May; 115(5):939-49. PubMed ID: 26791999
[TBL] [Abstract][Full Text] [Related]
7. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry.
Helmert S; Marten S; Mizera H; Reitter A; Sahin K; Tittl L; Beyer-Westendorf J
J Thromb Thrombolysis; 2017 Aug; 44(2):169-178. PubMed ID: 28643004
[TBL] [Abstract][Full Text] [Related]
9. Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care.
Kirchhof P; Pecen L; Bakhai A; de Asmundis C; de Groot JR; Deharo JC; Kelly P; Levy P; Lopez-de-Sa E; Monteiro P; Steffel J; Waltenberger J; Weiss TW; Laeis P; Manu MC; Souza J; De Caterina R
Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 9(1):47-57. PubMed ID: 35881467
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry.
Beyer-Westendorf J; Ebertz F; Förster K; Gelbricht V; Michalski F; Köhler C; Werth S; Endig H; Pannach S; Tittl L; Sahin K; Daschkow K; Weiss N
Thromb Haemost; 2015 Jun; 113(6):1247-57. PubMed ID: 25739533
[TBL] [Abstract][Full Text] [Related]
11. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation.
Okumura K; Akao M; Yoshida T; Kawata M; Okazaki O; Akashi S; Eshima K; Tanizawa K; Fukuzawa M; Hayashi T; Akishita M; Lip GYH; Yamashita T;
N Engl J Med; 2020 Oct; 383(18):1735-1745. PubMed ID: 32865374
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial.
Vilain K; Li H; Kwong WJ; Antman EM; Ruff CT; Braunwald E; Cohen DJ; Giugliano RP; Magnuson EA;
Circ Cardiovasc Qual Outcomes; 2020 Nov; 13(11):e006511. PubMed ID: 33148013
[TBL] [Abstract][Full Text] [Related]
13. The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Minguet J; Sims HM; Smith KH; Bramlage P
Expert Rev Clin Pharmacol; 2017 Jan; 10(1):5-15. PubMed ID: 27817212
[TBL] [Abstract][Full Text] [Related]
14. Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year data from the ETNA-AF-Europe study.
Kirchhof P; Bakhai A; de Asmundis C; de Groot JR; Deharo JC; Kelly P; Lopez-de-Sa E; Monteiro P; Fronk EM; Lamparter M; Laeis P; Smolnik R; Steffel J; Waltenberger J; Weiss TW; De Caterina R;
Int J Cardiol; 2024 Aug; 408():132118. PubMed ID: 38697397
[TBL] [Abstract][Full Text] [Related]
15. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
[TBL] [Abstract][Full Text] [Related]
16. Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study.
de Groot JR; Weiss TW; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Waltenberger J; Steffel J; Levy P; Bakhai A; Zierhut W; Laeis P; Manu MC; Reimitz PE; De Caterina R; Kirchhof P
Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f30-f39. PubMed ID: 32790837
[TBL] [Abstract][Full Text] [Related]
17. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
[TBL] [Abstract][Full Text] [Related]
18. Outcomes and Safety of Very-Low-Dose Edoxaban in Frail Patients With Atrial Fibrillation in the ELDERCARE-AF Randomized Clinical Trial.
Akashi S; Oguri M; Ikeno E; Manita M; Taura J; Watanabe S; Hayashi T; Akao M; Okumura K; Akishita M; Yamashita T
JAMA Netw Open; 2022 Aug; 5(8):e2228500. PubMed ID: 35997978
[TBL] [Abstract][Full Text] [Related]
19. 5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry.
Tittl L; Marten S; Naue C; Beyer-Westendorf J
Thromb Res; 2021 Jun; 202():24-30. PubMed ID: 33711755
[TBL] [Abstract][Full Text] [Related]
20. Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE-AF Randomized Clinical Trial.
Kuroda M; Tamiya E; Nose T; Ogimoto A; Taura J; Imamura Y; Fukuzawa M; Hayashi T; Akao M; Yamashita T; Lip GYH; Okumura K
JAMA Cardiol; 2022 Jun; 7(6):583-590. PubMed ID: 35416910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
